UNSPSC 51332882: Triflupromazine hydrochloride

This classification denotes a phenothiazine and antipsychotic agent with the molecular formula C18H19F3N2S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9E75N4A5HM, chemically known as 10h-phenothiazine-10-propanamine, n, n-dimethyl-2- (trifluoromethyl)-, monohydrochloride but more generally known as triflupromazine hydrochloride, which bears US NIH Compound Identifier 5568.

UNSPSC 51332882 Triflupromazine hydrochloride is a Commodity code nominally for a specific pharmaceutical chemical compound, but the recent state and local opportunities tagged under it address generic multi-source pharmaceuticals, naloxone, and pharmacy benefit management infrastructure rather than triflupromazine itself. The code shows a significant mismatch between its nominal scope and the actual work being solicited; state and local procurement offices are using this code to tag pharmaceutical procurement, drug deactivation systems, and pharmacy program initiatives without specificity to this single active pharmaceutical ingredient. The mix of issuing bodies includes county health departments (Seminole County, Florida), state health agencies (Texas HHS Commission), and state cooperative purchasing alliances (Minnesota MMCAP), reflecting the fragmented nature of state and local pharmaceutical procurement across multiple jurisdictions and purchasing structures.

Recent activity concentrates in Florida, Texas, and Minnesota. Seminole County issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, with bids due July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program—an exploratory solicitation designed to inform future RFP strategy rather than a competitive bid. Minnesota MMCAP, administered by the Minnesota Department of Administration's Office of State Procurement and serving participating states including Oregon, issued RFP S1070000015802 on January 20, 2026, establishing multiple contracts for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers (AmerisourceBergen Drug Corporation / Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC), with proposals due March 26, 2026. The MMCAP procurement evaluates vendors 75 percent on price competitiveness, 10 percent on fixed pricing for contract term, and 5 percent each on administrative fee format compliance, EDI capability, and agreement to a 3 percent administrative fee; contract term is two years for new responders with optional extensions.